dc.contributor.author | Bergueiro, Julián | |
dc.contributor.author | Glitscher, Emanuel A. | |
dc.contributor.author | Calderón, Marcelo | |
dc.date.accessioned | 2023-03-22T16:30:55Z | |
dc.date.available | 2023-03-22T16:30:55Z | |
dc.date.issued | 2022-06 | |
dc.identifier.citation | Biomaterials Advances 137 : (2022) // Article ID 212842 | es_ES |
dc.identifier.issn | 2772-9508 | |
dc.identifier.uri | http://hdl.handle.net/10810/60448 | |
dc.description.abstract | Temperature-trigger chemotherapy is one of the state-of-the-art anti-tumoral strategies in nanomedicine. However, this strategy is in close relationship with the effect of the temperature in the tumor tissue. With high temperatures, the ablation of the tumor tissue can hinder a correct chemotherapy approximation. On the other hand, with moderate temperatures a negative vascularization that promotes the tumor growing is produced and competes with the chemotherapeutic effects. We have constructed one nanogel system composed of a thermoresponsive polymer cross-linked by plasmonic gold nanoparticles (AuNPs) for temperature-trigger chemotherapy. Doxorubicin loaded in the porous interior of the nanogel is released when the thermoresponsive network of the nanogel collapses due to the heat generated by the AuNPs upon near infra-red light irradiation. The hybrid nanogel system has been tested in vitro and in vivo, where it was observed that the temperatures reached in the in vivo NIR irradiation have an undesired effect on the inhibition of the tumor growth while the drug loaded systems considerably reduced the tumor sizes. This study shows the importance of design in temperature triggered antitumoral systems, where lower temperatures usually reached in practical situations due to light attenuation produced by the tissue can be positively utilized for enhancing the antitumoral effect of loaded drugs in the system. | es_ES |
dc.description.sponsorship | We gratefully acknowledge financial support from the Bundesministerium für Bildung und Forschung (BMBF) through the NanoMatFutur award (13N12561, Thermonanogele). We would like to acknowledge the assistance of the Core Facility BioSupraMol supported by the Deutsche Forschungsgemeinschaft (DFG). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | nanogels | es_ES |
dc.subject | thermoresponsive | es_ES |
dc.subject | gold nanoparticles | es_ES |
dc.subject | photothermal agent | es_ES |
dc.subject | cancer therapy | es_ES |
dc.subject | nanocarrier | es_ES |
dc.subject | drug delivery | es_ES |
dc.title | A hybrid thermoresponsive plasmonic nanogel designed for NIR-mediated chemotherapy | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | © 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/). | es_ES |
dc.rights.holder | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S2772950822001194?via%3Dihub | es_ES |
dc.identifier.doi | 10.1016/j.bioadv.2022.212842 | |